FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time
Phase 2CompletedDevelopment Stage
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Dec 1, 2007 → Dec 1, 2008
About FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time
FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time is a phase 2 stage product being developed by Baxter for Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts). The current trial status is completed. This product is registered under clinical trial identifier NCT00576420. Target conditions include Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts).
What happened to similar drugs?
0 of 3 similar drugs in Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts) were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00576420 | Phase 2 | Completed |
Competing Products
4 competing products in Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TISSEEL Lyo | Baxter | Phase 3 | 37 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2 | 32 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 29 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 37 |